Product Portfolio



PRODUCT	INDICATION	Partner	Territory	Phase	EXPECTED LAUNCH YEAR
				Development / Pre-Submission / Submitted / Approved / Marketed	
Oncology/Hematology					
Akynzeo®	Chemotherapy-induced nausea & vomiting	Helsinn	Canada Brazil Argentina	Marketed	—
Aloxi®/Onicit®	Chemotherapy-induced nausea & vomiting	Helsinn	Canada Brazil Mexico	Marketed	—
Trelstar®	Prostate cancer	Debiopharm	Canada	Marketed	—
Orgovyx®	Prostate cancer	Sumitomo	Canada	Approved	—
Vidaza®	Myelodysplastic syndrome	BMS	Brazil	Marketed	—
Abraxane®	Pancreatic cancer	BMS	Brazil	Marketed	—
Halaven®	Breast cancer & sarcoma	Eisai	Brazil Argentina Colombia	Marketed	—
Lenvima®	Thyroid cancer & hepatocellular carcinoma	Eisai	Brazil Colombia	Marketed	—
Lenvima®	Renal cell carcinoma	Eisai	Brazil	Marketed	—
Minjuvi®	Relapsed/refractory diffuse large B-cell lymphoma	Incyte	Brazil Argentina Mexico	Approved	—
Minjuvi®	First-line diffuse large B-cell lymphoma	Incyte	Brazil Argentina Mexico	Submitted	2028-2030
Minjuvi®	Relapsed/refractory follicular lymphoma	Incyte	Brazil Argentina Mexico	Marketed Submitted Approved	— 2027 —
Zynyz®	Squamous cell carcinoma of the anal canal & Merkel cell carcinoma	Incyte	Brazil Argentina Colombia Mexico	Pre-Submission	2028-2031
Niktimvo®	Chronic graft-versus-host disease	Incyte	Brazil Argentina Mexico	Approved Pre-Submission	2027-2029
Pemazyre®	Cholangiocarcinoma	Incyte	Brazil Argentina Mexico	Marketed	—
Tavalisse®	Chronic immune thrombocytopenia	Rigel	Brazil Colombia Mexico	Marketed Approved Marketed	— 2027 —
Poteligeo®	Relapsed or refractory mycosis fungoides or Sézary syndrome	KKI	Brazil Argentina Colombia Mexico	Pre-Submission	2028-2031
BGx					
Palbocil®, Bapocil®[1]	Breast cancer	Own	Argentina Colombia	Marketed	—
Xetrane®[1]	Multiple myeloma	Own	Argentina Colombia	Marketed Submitted	— 2028-2029
Xetrane®[1]	AIDS-related kaposi sarcoma	Own	Argentina	Marketed	—
Ladevina®[1]	Multiple myeloma & myelodysplastic syndrome	Own	Argentina Colombia	Marketed	—
Ladevina®[1]	Mantle cell lymphoma	Own	Argentina	Marketed	—
Zyvalix®[1]	Prostate cancer	Own	Argentina Colombia	Marketed	—
Karfib®[1]	Relapsed/refractory multiple myeloma	Own	Argentina	Marketed	—
Leprid®[1]	Prostate cancer	Own	Argentina	Marketed	—
Rembre®[1]	Chronic myeloid & acute lymphoblastic leukemia	Own	Argentina Colombia	Marketed	—
Molapib®[1]	Ovarian, fallopian tube, or peritoneal cancer	Own	Argentina Colombia	Marketed Pre-Submission	— 2029-2030
O501[1]	Oncology/hematology	Own	Argentina	Approved	2027
O503[1]	Oncology/hematology	Own	Argentina	Pre-Submission	2027-2028
O504[1]	Oncology/hematology	Own	Argentina	Development	2030

Product Portfolio

Pipeline Product
Strategic or Mature Product

PRODUCT	INDICATION	Partner	Territory	Phase	EXPECTED LAUNCH YEAR
				Development / Pre-Submission / Submitted / Approved / Marketed	
O401	Oncology/hematology		Brazil	Development	2030
O402	Oncology/hematology		Brazil	Development	2030
H402	Oncology/hematology		Brazil Colombia	Development	2031
H403	Oncology/hematology		Brazil Colombia	Development	2030
Infectious Diseases					
Ambisome®	Invasive fungal infection	Gilead	Brazil	Marketed	—
Cresemba®	Invasive fungal infection	Basilea	Brazil Argentina Colombia Mexico	Marketed	—
Impavido®	Leishmaniasis	Own	Other	Marketed	—
BGx					
Dolufevir®[1]	HIV infection	Own	Argentina	Marketed	—
Neurology					
Exelon®	Dementia associated with Alzheimer's and Parkinson's disease	Own	Canada Brazil Argentina Colombia Mexico	Marketed	—
Dexedrine®	ADHD	Own	Canada	Marketed	—
Crexont®	Parkinson's disease	Amneal	Canada Brazil Argentina Colombia Mexico	Approved	2028-2030
Qelbree®	ADHD	Supernus	Canada	Submitted	2028-2029
Jornay PM®	ADHD	Collegium	Canada	Marketed	—
			Argentina Mexico	Submitted	2031
Xcopri®	Partial-onset seizures & epilepsy	SK	Canada	Marketed	—
BGx					
Durivast®	Dementia associated with Alzheimer's	Luye	Colombia	Marketed	—
Other Specialty					
Imvexxy®	Menopause health	TXMD	Canada	Marketed	—
Bijuva®	Menopause health	TXMD	Canada	Marketed	—
Salofalk®	Inflammatory bowel disease	Dr. Falk	Argentina Colombia	Marketed	—
Ursofalk®	Primary biliary cirrhosis	Dr. Falk	Argentina Colombia	Marketed	—
Testim®	Testosterone deficiency	Endo	Canada	Marketed	—
Envarsus®PA	Solid organ transplantation	Veloxis	Canada	Marketed	—
Myfembree®	Uterine fibroids & endometriosis	Sumitomo	Canada	Marketed	—
Wynzora®	Plaque psoriasis	MC2	Canada	Marketed	—
Gemtesa®	Overactive bladder	Sumitomo	Canada	Approved	2028
BGx					
Fibridoner®[1]	Idiopathic pulmonary fibrosis	Own	Argentina	Marketed	—

[1] Products developed by Knight's internal BGx capabilities in Argentina. Unless otherwise noted in above table, these products are marketed in Argentina.

Development: Products under development stage.
Pre-submission: Not yet submitted for regulatory review. The indication is the anticipated indication upon regulatory approval.
Submitted: Currently under regulatory review. The indication is the anticipated indication upon regulatory approval.
Approved: Approved by regulatory authorities but not yet commercially launched.

See MD&A for more details